Login to Your Account

Lipoxen Simultaneously Acquires Symbiotec

Russia's SynBio Purchases Majority Stake in UK's Lipoxen

By Nuala Moran

Monday, August 8, 2011
LONDON – Drug delivery specialist Lipoxen plc is selling a majority, £12.8 million (US$20.9 million), stake in the company to SynBio LLC, a firm that is majority-owned by the government of Russia, as one of a series of moves to transform itself into a mainstream drug developer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription